Search
EURopean trial On reduction of cardiac events with Perinopril in stable coronary Artery disease (EUROPA) trial
Study design:
1) 12,218 patients with:
a) stable coronary artery disease (CAD)
b) no heart failure
2) perindopril target dose 8 mg QD vs. placebo
3) standard CAD therapy
4) mean follow-up of 4.2 years
5) randomized study supported by manufacturer of perindopril
Results:
1) rate of cardiovascular death, nonfatal myocardial infarction or cardiac arrest with successful rescuscitation was significantly lower in perindopril group than placebo group (8% vs 10%)
2) benefit evident even among patients taking:
a) beta-blocker
b) hypolipidemic agent
c) calcium channel blocker
3) benefit evident in diabetic patients
4) perindopril lowered blood pressure by an average of:
a) 5 mm Hg systolic
b) 2 mm Hg diastolic
5) improved outcomes noted in patients with or without hypertension
Related
PEACE study
General
clinical trial
References
- Journal Watch 23(22):175-76, 2003
EURopean trial On reduction of cardiac events with Perinopril
in stable coronary Artery disease (EUROPA) Investigators,
- Fox KM; EURopean trial On reduction of cardiac events with
Perindopril in stable coronary Artery disease Investigators.
Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Lancet. 2003 Sep 6;362(9386):782-8.
PMID: 13678872